

Anti-HGFR/c-Met Antibody (Amivantamab)

Introduction

Amivantamab (JNJ-61186372) is a humanized EGFR-MET bispecific antibody with immunohistochemical anticancer activity. Amivantamab can inhibit ligand binding, promote endocytosis and degradation of receptor-antibody complexes, and induce Fc-dependent endocytosis of macrophages and antibody-dependent cellular cytotoxicity of natural killer cells.

Product parameters

Alternative Names	RYBREVANT, JNJ-61186372
Target Accession	P08581
Target	HGFR / c-Met
CAS number	2171511-58-1
Molecular Weight	145.88 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human cMet His at 2 ug/mL can bind Anti-HGFR/c-Met Antibody (Amivantamab), EC50=0.006091 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

